ColgatePalmolive (CL) Q2 2025 earnings review
Growth Stalls and Margins Reverse as Cautious Consumer Bites
Colgate-Palmolive's growth momentum came to a halt in Q2, with Organic Sales slowing to just 1.8%. After six quarters of expansion, GAAP Gross Margin contracted 50 bps YoY, signaling an end to a key P&L tailwind. Persistent weakness in North America (-0.9% organic) and significant FX headwinds in Latin America overshadowed solid profitability in the Hill's Pet Nutrition segment. Management acknowledged a 'persistently cautious consumer' and trimmed its full-year organic sales growth outlook to the low end of the 2-4% range, signaling a challenging second half.
🐂 Bull Case
Despite slowing organic sales (+2.0%), the Hill's Pet Nutrition segment delivered a 13% increase in operating profit and a 180 bps margin expansion, remaining a critical profit engine for the company.
The Europe division continued to perform well, with net sales up 7.8% and operating profit growing 9%, demonstrating the success of its premium multi-brand strategy in a tough environment.
The company announced a new 3-year productivity program aimed at funding its 2030 strategic plan, suggesting a forward-looking approach to generating savings and reinvesting in growth capabilities like AI and innovation.
🐻 Bear Case
Organic sales growth has decelerated sharply from 6.8% two quarters ago to 1.8%. Management effectively lowered full-year guidance to the low end of its 2-4% range, confirming the weaker trend.
After a year and a half of expansion, gross margins contracted YoY. Management cited rising raw material costs, indicating that a key tailwind for earnings growth has reversed.
The key North America segment posted its third consecutive quarter of negative organic sales growth (-0.9%) while operating profit fell 9% and margins compressed by 170 basis points.
⚖️ Verdict: 🔴
Bearish. The sharp deceleration in organic growth and the negative inflection in gross margin are significant concerns. Persistent underperformance in the core North American market and a cautious consumer outlook, confirmed by the trimmed guidance, outweigh the pockets of strength in Hill's profitability and Europe. The growth story has clearly weakened.
Key Themes
North America Remains a Drag on Performance
The North American division continues to struggle, posting its third consecutive quarter of negative organic sales (-0.9%). The issue is hitting the bottom line hard, with operating profit falling 9% and operating margin compressing a significant 170 basis points to 18.9%. Management attributes the weakness to a 'persistently cautious consumer', but the ongoing underperformance points to deeper competitive challenges.
Gross Margin Expansion Reverses
After six consecutive quarters of YoY improvement, gross margin contracted by 50 basis points to 60.1%. This reversal signals an end to a powerful P&L tailwind that had been funding reinvestment. Management cited higher raw material costs, specifically in palm, vegetable oils, and tallow, which are now offsetting any benefits from lower tariffs. Full-year guidance for 'roughly flat' margins implies continued pressure in the second half.
Hill's Delivers on Profitability
While Hill's organic sales growth slowed to 2.0%, its profitability was a major bright spot. The segment grew operating profit by 13%, with margins expanding an impressive 180 basis points to 22.9%. According to management, this is driven by a favorable mix shift, with the higher-margin therapeutic side of the business growing faster than the wellness side. This segment remains a crucial contributor to the company's bottom line.
Global Consumer Caution is a Clear Headwind
Management repeatedly highlighted a cautious consumer as a primary reason for slowing growth, particularly in North America, but also noted deceleration in Brazil. To combat this, the company is focusing on 'price pack architecture' to offer value through different sizes and multipacks. This macro pressure is the key driver behind the decision to guide to the low end of the organic sales range for the full year.
Contradiction: Brand Strength vs. Market Reality
Management continues to emphasize the strength of its brands and innovation as key drivers. However, this narrative is contradicted by the data: organic growth has nearly evaporated from 6.8% to 1.8% in two quarters, the key North American market has been in decline for nine months, and the company pulled back on advertising spend YoY this quarter ($678M vs $706M) at a time when stimulating demand seems most critical.
New Productivity Program to Fund Future Growth
The company announced a new 3-year productivity initiative, projecting $200-$300 million in pre-tax charges. This program is designed to fund investments for its 2030 strategic plan, focusing on accelerating innovation, enhancing data & AI capabilities, and optimizing the supply chain. This proactive measure aims to create P&L flexibility and fuel growth in a slower top-line environment.
Other KPIs
Stable. Inventories rose 10.3% YoY, significantly outpacing the 1.0% growth in net sales. This suggests a potential build-up of stock that may have been caused by weaker-than-anticipated consumer demand. This trend warrants monitoring as it could lead to future promotional activity or production cuts if sales do not accelerate in the second half.
Reversing. While the segment delivered a respectable +3.4% organic sales growth, it was completely erased by a severe -8.2% negative impact from foreign exchange. This resulted in a reported sales decline of -4.8% and a steep -12% drop in operating profit, highlighting the company's significant exposure to currency volatility in emerging markets.
Decelerating. Advertising spend decreased by 4% YoY and fell as a percentage of sales to 13.3% from 13.9% a year ago. This pullback contrasts with prior quarters of heavy investment and is surprising given the focus on driving volume in a slowing consumer environment.
Guidance
Decelerating. This is a trim from the prior 2% to 4% range, implying a target closer to 2.5%. With H1 organic growth at 1.6%, this guidance requires an acceleration to ~3.4% in the second half. Management expects this to be driven by innovation and an improving category environment, but it remains a challenging target given current trends.
Decelerating. This guidance is unchanged. However, given the +80 bps expansion in Q1 and -50 bps contraction in Q2 (net +10 bps YTD), 'roughly flat' for the full year implies a continued YoY decline in gross margin for the second half of 2025.
Stable. This guidance is unchanged. With YoY EPS growth of +2.4% in Q1 and +2.2% in Q2, this outlook suggests management expects a similar pace of earnings growth to continue through the rest of the year.